CareDx, Inc. (NASDAQ:CDNA) Holdings Decreased by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. trimmed its holdings in CareDx, Inc. (NASDAQ:CDNA - Free Report) by 8.1% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,376,754 shares of the company's stock after selling 121,264 shares during the period. Sumitomo Mitsui Trust Group Inc. owned about 2.48% of CareDx worth $24,437,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Sterling Capital Management LLC raised its position in shares of CareDx by 771.2% during the 4th quarter. Sterling Capital Management LLC now owns 1,272 shares of the company's stock valued at $27,000 after acquiring an additional 1,126 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in CareDx by 553.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,922 shares of the company's stock worth $84,000 after acquiring an additional 3,322 shares during the last quarter. State of Wyoming acquired a new position in CareDx in the fourth quarter valued at approximately $91,000. Plato Investment Management Ltd boosted its stake in CareDx by 34.1% in the fourth quarter. Plato Investment Management Ltd now owns 5,390 shares of the company's stock valued at $116,000 after acquiring an additional 1,370 shares during the period. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd grew its holdings in shares of CareDx by 41.5% during the fourth quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 9,343 shares of the company's stock valued at $200,000 after purchasing an additional 2,742 shares during the last quarter.

Analysts Set New Price Targets

CDNA has been the topic of several recent research reports. Stephens reissued an "overweight" rating and issued a $40.00 price target on shares of CareDx in a report on Monday, May 5th. Wall Street Zen cut CareDx from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. HC Wainwright reissued a "neutral" rating and set a $25.00 price target on shares of CareDx in a report on Monday, May 5th. Finally, The Goldman Sachs Group dropped their price objective on shares of CareDx from $34.00 to $26.00 and set a "buy" rating on the stock in a report on Thursday, April 17th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, CareDx currently has an average rating of "Moderate Buy" and a consensus price target of $30.33.

CareDx Price Performance

Shares of NASDAQ CDNA traded down $0.30 during midday trading on Thursday, reaching $19.20. 309,715 shares of the company traded hands, compared to its average volume of 915,305. The company has a market cap of $1.07 billion, a price-to-earnings ratio of 16.69 and a beta of 2.19. The stock has a 50-day moving average price of $17.76 and a 200 day moving average price of $19.78. CareDx, Inc. has a 52 week low of $14.09 and a 52 week high of $34.84.

CareDx (NASDAQ:CDNA - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The company reported $0.09 EPS for the quarter, beating analysts' consensus estimates of $0.06 by $0.03. The business had revenue of $84.69 million for the quarter, compared to analyst estimates of $84.56 million. CareDx had a net margin of 19.79% and a return on equity of 21.16%. The business's revenue for the quarter was up 17.6% on a year-over-year basis. During the same quarter last year, the business earned ($0.03) earnings per share. As a group, analysts expect that CareDx, Inc. will post -0.9 EPS for the current year.

Insider Buying and Selling at CareDx

In other news, Director William A. Hagstrom sold 19,391 shares of the company's stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $19.90, for a total transaction of $385,880.90. Following the completion of the sale, the director directly owned 53,979 shares of the company's stock, valued at $1,074,182.10. This represents a 26.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Hannah Valantine sold 10,570 shares of the business's stock in a transaction dated Wednesday, June 18th. The stock was sold at an average price of $19.16, for a total value of $202,521.20. Following the sale, the director owned 38,994 shares in the company, valued at approximately $747,125.04. The trade was a 21.33% decrease in their position. The disclosure for this sale can be found here. Insiders sold 129,343 shares of company stock valued at $2,238,811 in the last ninety days. Company insiders own 4.40% of the company's stock.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.